Kelley, Robin Kate http://orcid.org/0000-0002-1984-2430
Miksad, Rebecca
Cicin, Irfan
Chen, YenHsun
Klümpen, Heinz-Josef
Kim, Stefano
Lin, Zhong-Zhe
Youkstetter, Jillian
Hazra, Saswati
Sen, Suvajit
Cheng, Ann-Lii http://orcid.org/0000-0002-9152-6512
El-Khoueiry, Anthony B.
Meyer, Tim http://orcid.org/0000-0003-0782-8647
Abou-Alfa, Ghassan K.
Funding for this research was provided by:
Exelixis
Article History
Received: 9 February 2021
Revised: 22 July 2021
Accepted: 19 August 2021
First Online: 7 October 2021
Ethics approval and consent to participate
: CELESTIAL was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was approved by the ethics committee/institutional review board of participating study centers. All patients provided written informed consent.
: Not applicable.
: RKK: Consulting/advisory: Agios, AstraZeneca, BMS, Exact Sciences, Genentech/Roche, Gilead, Ipsen, Merck; research funding: Adaptimmune, Agios, AstraZeneca, Bayer, BMS, Celgene, Eli Lily, EMD Serono, Exelixis, MedImmune, Merck, Novartis, Partner Therapeutics, Taiho Pharmaceuticals. RM<b>:</b> Employee of Flatiron Health, equity ownership Flatiron Health, stock ownership Roche. Consulting: De Luca Foundation. IC<b>:</b> Consulting/advisory: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Quintiles; research funding: Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Merck, Merck Serono, Parexel, Pfizer, Quintiles, Taiho. YC, ZZL: Nothing to report. HJK: Consulting/advisory: Ipsen; research funding: Bayer, BTG, Daichii, Exelixis, Ipsen, ITM, Novartis, Sirtex, Taiho. SK: Honorarium: Bayer, Boehringer, Ipsen, MSD, Sanofi, Servier; research funding: Pfizer, Roche, Sanofi. JY, SH, SS<b>:</b> Employees of Exelixis. ALC<b>:</b> Honorarium: Bayer, Eisai, Merck, Merck Serono, Novartis, Ono Pharma., Roche, IQVIA; consulting/advisory: Bayer, BMS, Eisai, Exelixis, IQVIA, Merck Serono, Novartis, Nucleix, Ono Pharma., Roche; speaker bureau fees: Amgen, Bayer, Novartis, Eisai, Ono Pharma. Yakuhin. ABEK<b>:</b> Consulting/advisory: AstraZeneca, Bayer, BMS, Celgene, CytomX, Eisai, Exelixis, Novartis, Roche; grant support: AstraZeneca, Astex; speakers’ bureau fee: Merrimack. TM<b>:</b> Grant support/consulting: Bayer, BMS, BTG, Eisai, Merck. GKAA<b>:</b> Grant support: ActaBiologica, Agios, AstraZeneca, Bayer, Beigene, Berry Genomics, BMS, Casi, Celgene, Exelixis, Genentech/Roche, Halozyme, Incyte, Mabvax, Puma, QED, Sillajen, Yiviva; consulting/advisory: Agios, AstraZeneca, Autem, Bayer, Beigene, Berry Genomics, Celgene, CytomX, Debio, Eisai, Eli Lilly, Flatiron, Genentech/Roche, Gilead, Incyte, Ipsen, LAM, Loxo, Merck, MINA, Polaris, QED, Redhill, Silenseed, Sillajen, Sobi, Therabionics, Twoxar, Vector, Yiviva.